These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16830315)

  • 1. Intravenous flumazenil for Parkinson's disease: a single dose, double blind, placebo controlled, cross-over trial.
    Ondo WG; Silay YS
    Mov Disord; 2006 Oct; 21(10):1614-7. PubMed ID: 16830315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease.
    Ondo WG; Hunter C
    Mov Disord; 2003 Jun; 18(6):683-5. PubMed ID: 12784272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study.
    Van der Rijt CC; Schalm SW; Meulstee J; Stijnen T
    Gastroenterol Clin Biol; 1995; 19(6-7):572-80. PubMed ID: 7590022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.
    Hauser RA; Lyons KE; McClain T; Carter S; Perlmutter D
    Mov Disord; 2009 May; 24(7):979-83. PubMed ID: 19230029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
    Pahwa R; Koller WC; Trosch RM; Sherry JH;
    J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial.
    Nutt JG; Carter JH; Carlson NE
    Arch Neurol; 2007 Mar; 64(3):319-23. PubMed ID: 17353373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
    Simon N; Micallef J; Reynier JC; Lesourd M; Witjas T; Alicherif A; Azulay JP; Blin O
    Mov Disord; 2005 Jul; 20(7):803-9. PubMed ID: 15726579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute tryptophan depletion on cognition, memory and motor performance in Parkinson's disease.
    Scholtissen B; Verhey FR; Adam JJ; Prickaerts J; Leentjens AF
    J Neurol Sci; 2006 Oct; 248(1-2):259-65. PubMed ID: 16756999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease.
    Putzki N; Maschke M; Drepper J; Diener HC; Timmann D
    J Neurol; 2002 Jul; 249(7):824-8. PubMed ID: 12140664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group.
    Clin Ther; 1992; 14(6):978-95. PubMed ID: 1286503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials.
    Gunzler SA; Pavel M; Koudelka C; Carlson NE; Nutt JG
    Clin Neuropharmacol; 2009; 32(2):97-102. PubMed ID: 18978495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.
    Lou JS; Kearns G; Benice T; Oken B; Sexton G; Nutt J
    Mov Disord; 2003 Oct; 18(10):1108-14. PubMed ID: 14534913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.